Foliglurax Fails to Minimize Long-term Use Side Effects of Levodopa, Phase 2 Trial Shows

Foliglurax Fails to Minimize Long-term Use Side Effects of Levodopa, Phase 2 Trial Shows
Despite being safe and well-tolerated, foliglurax (PTX002331), an investigational therapy for Parkinson’s disease, failed to significantly reduce some of the effects associated with long-term use of levodopa, including its “wearing-off” effect and motor complications, according to data from a Phase 2 clinical trial. As a result, Lundbeck, the company that currently holds the therapy’s development and commercial rights, has decided ... read more
Source: Parkinson’s News TodayPublished on 2020-04-03By Joana Carvalho, PhD